Skip to main content
Clinical Trials/EUCTR2016-002171-94-BE
EUCTR2016-002171-94-BE
Active, not recruiting
Phase 1

Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A multicentre randomized clinical study - Newrofeed

Mensia Technologies SA0 sites179 target enrollmentJanuary 20, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Attention Deficit-Hyperactivity Disorder
Sponsor
Mensia Technologies SA
Enrollment
179
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 20, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Mensia Technologies SA

Eligibility Criteria

Inclusion Criteria

  • \-Children or adolescents (male or female) aged 7\-13 years
  • \-ADHD diagnosis positive with Kiddie\-Sads
  • \-ADHD RS IV \>6 for attention, with or without hyperactivity
  • \-Patient having already had corrective actions for ADHD (formal and informal educational support, psychoeducation, psychotherapy, occupational therapy remediation, at\-school programs and remediations)
  • \-Signature of inform consent form by parent and child
  • \-Wireless internet connection at home
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 179
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • \-ADHD hyperactive/Impulsive without inattention component
  • \-Established diagnosis of epilepsy or other neurological disorders
  • \-Severe psychiatric disorder other than ADHD diagnosed with Kiddie\-Sads such as autism, schizophrenia, severe generalized anxiety disorder, major depression or severe tics
  • \-Patient with comorbid disorder requiring psychoactive medication other than ADHD medication
  • \-Patient having already been treated with psycho\-active drug (MPH and others) or EEG\-NF for ADHD in the last 6 months, or more than 4 weeks more than 6 months ago
  • \-Unable to use the solution (tablet use and/or headset set\-up and/or understanding instructions) according to the investigator
  • \-Absence of wireless internet connection at home
  • \-Medical disorder requiring systemic chronic medication with confounding psychoactive effects
  • \-IQ \< 80 using the 3 subtest form of the WASI or the WISC
  • \-Plans to move requiring centre change during the next 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials